Deep Brain Stimulation and Cognitive Decline in Parkinson’s Disease: A Clinical Review by João Massano & Carolina Garrett
REVIEW ARTICLE
published: 26 April 2012
doi: 10.3389/fneur.2012.00066
Deep brain stimulation and cognitive decline in Parkinson’s
disease: a clinical review
João Massano1,2,3* and Carolina Garrett 1,2,3
1 Movement Disorders and Functional Surgery Unit, Centro Hospitalar de São João, Porto, Portugal
2 Department of Neurology, Centro Hospitalar de São João, Porto, Portugal
3 Department of Clinical Neuroscience and Mental Health, Faculty of Medicine, University of Porto, Porto, Portugal
Edited by:
Oscar López, University of Pittsburgh
School of Medicine, USA
Reviewed by:
Oscar López, University of Pittsburgh
School of Medicine, USA
Marcelo L. Berthier, University of
Malaga, Spain
*Correspondence:
João Massano, Movement Disorders
and Functional Surgery Unit,
Department of Neurology, Centro
Hospitalar de São João, Alameda
Prof. Hernâni Monteiro, 4200-319
Porto, Portugal.
e-mail: jmassano@med.up.pt
Parkinson’s disease is a common and often debilitating disorder, with a growing prevalence
accompanying global population aging. Current drug therapy is not satisfactory enough for
many patients, especially after a few years of symptom progression. This is mainly due
to the motor complications that frequently emerge as disease progresses. Deep brain
stimulation (DBS) is a useful therapeutic option in carefully selected patients that signiﬁ-
cantly improves motor symptoms, functional status, and quality of life. However, cognitive
impairment may limit patient selection for DBS, as patients need to have sufﬁcient mental
capabilities in order to understand the procedure, as well as its beneﬁts and limitations,
and cooperate with the medical team throughout the process of selection, surgery, and
postsurgical follow-up. On the other hand it has been observed that certain aspects of
cognitive performance may decline after DBS, namely when the therapeutic target is the
widely used subthalamic nucleus. These are important pieces of information for patients,
their families, and health care professionals. This manuscript reviews these aspects and
their clinical implications.
Keywords: Parkinson’s disease, cognitive impairment, deep brain stimulation, dementia, functional impairment,
globus pallidus interna, quality of life, subthalamic nucleus
INTRODUCTION
Parkinson’s disease (PD) is a common, potentially disabling neu-
rodegenerative disease (Massano and Bhatia, 2012). It was esti-
mated that, in 2005, more than 4 million people in the world
suffered from this disorder, and disease prevalence is estimated to
escalate in the future, as the mean age of the population increases
at a worldwide level (Dorsey et al., 2007). Following the original
clinical depictions by Parkinson (1817) in the nineteenth century,
motor features of the disease, such as bradykinesia, resting tremor,
rigidity, and gait and postural changes, were regarded for a long
time as the major features of PD. This view has changed in the past
few decades, as a growing number of clinicians and researchers
have studied and reported in detail on the important non-motor
characteristics of the disease (Chaudhuri and Schapira, 2009; Gal-
lagher et al., 2010). Among them is cognitive decline, ranging from
mild impairment to overt dementia – a contemporary review on
this topic can be found included in the present Frontiers Research
Topic collection (Meireles and Massano, submitted).
The treatment of PD is not a straightforward task, especially
when dealing with newly diagnosed patients and, especially, in
advanced disease stages. In the early stages there is controversy
regarding the timing of therapy initiation and which speciﬁc
strategies should be used. Many clinicians tend to initiate drug
therapy as soon as symptoms interfere with the patient’s lifestyle,
usually prescribing monoamino oxidase B inhibitors or dopamin-
ergic agonists, especially in younger patients, but this approach
is under dispute within the scientiﬁc community – for instance,
opposite views support the notion that levodopa is the drug of
choice regardless of patient age or disease stage (Lang, 2009; Lees
et al., 2009; Schapira, 2009). Deep brain stimulation (DBS) has
become a standard of care for a signiﬁcant minority of patients
in advanced disease stages, with controlled trials and large clinical
series supporting its use, as both beneﬁts and safety have been well
established (Krack et al., 2003;Deuschl et al., 2006;Kleiner-Fisman
et al., 2006;Weaver et al., 2009; Follett et al., 2010;Moro et al., 2010;
Smeding et al., 2011). Patients selected for the procedure are typi-
cally not satisﬁedwith the severity of their symptoms anddisability
even under optimized medical therapy, especially due to the quite
incapacitating and frustrating motor complications, such as peak
dose dyskinesias, prolonged off periods, or sudden off states (Lang
et al., 2006; Massano and Bhatia, 2012). In most occasions, one of
two different brain regions is currently targeted for DBS in PD: the
subthalamic nucleus (STN) or the globus pallidus interna (GPi).
The ventral intermediate (VIM) nucleus of the thalamus was the
ﬁrst electrically stimulated region for the treatment of PD (Ben-
abid et al., 1987), but it is now targeted in uncommon and much
selected circumstances, as tremor is apparently the only clinical
feature improving signiﬁcantly with the procedure (Walter and
Vitek, 2004; Moro and Lang, 2006; Pahwa et al., 2006). The choice
of brain target for DBS should probably be carried out according
to each patient’s characteristics, as we will further detail in the text.
Cognitive impairment plays an important role in PD patients
who are potential candidates for DBS, as this may be a limiting
factor during patient selection. Also, evidence has been accumu-
lating regarding changes in cognitive performance after DBS, and
both physicians and patients should be well aware of this prior to
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the procedure. This review will approach these matters, and the
implications for clinical management.
METHODS
The authors conducted a PubMed search for papers published
between 1990 and August 2011. Keywords used were “PD,” “cog-
nition,” “cognitive decline,” and “DBS.” Relevant references were
chosen and an additional manual reference search was carried
out on the reference list in retrieved manuscripts; articles were
included for analysis only if the research enrolled at least 15 sub-
jects undergoing DBS, except where evidence was much scarcer
and only smaller series were available. The ﬁnal reference list was
produced on the basis of importance to the topics covered in this
review. Data were extracted from relevant sources and the text was
devised according to a predeﬁned structure.
COGNITIVE STATUS AS A KEY FACTOR FOR PATIENT
SELECTION FOR DBS IN PD
Accurate PD patient selection is paramount in DBS. This has been
acknowledged in the widely used core assessment program for
surgical interventional therapies in PD (CAPSIT-PD) protocol, a
landmark document in this ﬁeld (Defer et al., 1999). Patient cog-
nitive status is of utmost importance when considering DBS as a
potential therapy for PD, as patients displaying signiﬁcant cogni-
tive decline are generally not considered good candidates for the
procedure (Pillon, 2002; Lang et al., 2006; Moro and Lang, 2006;
Okun et al., 2007; Rodriguez et al., 2007; Bronstein et al., 2011).
This is due to several reasons, with ethical imperatives always in
mind as a background for clinical thinking and action. First, it
must be assured that the procedure is expected to help the patients
(beneﬁcence) and not harm them (non-maleﬁcence). Moreover,
effective and safer therapies should be thoroughly tried before pro-
ceeding with DBS, and beneﬁts should be wisely balanced against
risks (proportionality and subsidiarity; Clausen, 2010; Schermer,
2011). Such equilibrium may at times be difﬁcult to perceive when
considering speciﬁc therapeutic interventions, such as DBS,which
is often a publicly gloriﬁed intervention, and commonly under-
stood as a last resort (Bell et al., 2011). Another important issue is
that of autonomy, meaning that the patient must be able to decide
freely and in a fully informed manner whether he/she wishes to
proceed with the therapy (Clausen, 2010; Schermer, 2011). This
principle implies that the patient must have a cognitive status
that makes him/her able to understand the information given
by the clinicians, and carry out every relevant decisions in this
regard. These important ethical imperatives should be actively
safeguarded by the team involved in patient care at all times. On
the other hand, cognitive status is also important from a practical
perspective, as patients must be able to go through all required
presurgical selection procedures, to collaborate with the team in
the operating theater (patients are awake during surgery in most
centers), and to comply with the postsurgical follow-up program,
including serial DBS parameter adjustments. This can be very
demanding, due to the high number of visits often required and
the amount of time consumed, as well as the need for a skilled and
persistent programmer (Volkmann et al., 2006).
Despite the amount of knowledge gathered in the past
decades in the ﬁeld of DBS, several caveats, and important
uncertainties still remain. When someone is clearly demented it
is straightforward that he/she should not be offered the proce-
dure. Nevertheless, milder forms of cognitive decline occur in
PD, even at early disease stages (Caviness et al., 2007; Barone
et al., 2011; Domellöf et al., 2011; Meireles and Massano, sub-
mitted) and this should be taken into account when selecting
patients for DBS, but drawing safe selection boundaries with
regard to cognitive capacities is not an easy assignment. Even a
recent international multidisciplinary expert consensus meeting
was unable to come up with ﬁrm recommendations regarding
the best way of assessing these patients and the cutoff scores
that should be used in neuropsychological testing (Bronstein
et al., 2011). Some cognitive features have been clearly associ-
ated with PD (Emre et al., 2007; Goetz et al., 2008; Williams-Gray
et al., 2009; Barone et al., 2011), while others should rise sus-
picion about concomitant pathologies, such as the characteristic
early and predominant decline of episodic (hippocampal) mem-
ory seen in Alzheimer’s disease (Mayeux, 2010; Ballard et al.,
2011; McKhann et al., 2011). Physicians should be extraordi-
narily cautious in these circumstances, as accelerated cognitive
decline would probably be expected in such patients, as com-
pared to those with isolated PD pathology. Concurrent mixed
pathology might not be an uncommon happening (Jellinger and
Attems, 2008; Kovacs et al., 2008), and imaging research has shown
that a pattern of atrophy typical of AD may predict cognitive
decline in PD (Weintraub et al., 2012). Therefore, it is imper-
ative that detailed neuropsychological testing is performed and
data thoroughly reviewed and interpreted before a ﬁnal deci-
sion is reached about DBS in a particular patient. Normalized
tests and data should be used whenever possible, thus aiming
at the highest standards and accuracy of cognitive testing and
interpretation.
COGNITIVE DECLINE FOLLOWING DEEP BRAIN
STIMULATION IN PD
STN VERSUS GPi
A number of studies have looked at how cognition might be
affected following DBS in PD, especially when STN is the target.
Cognitive changes have been reported despite the fact that patients
undoubtedly improve from the motor standpoint and quality of
life (QOL; Deuschl et al., 2006; Kleiner-Fisman et al., 2006; Follett
et al., 2010; Smeding et al., 2011). This implies that DBS produces
effects both on motor and cognitive neural networks, probably
due to the fact that the targeted nuclei are also involved in asso-
ciative processes, thus explaining the impact of DBS on cognition
(Temel et al., 2005; Mallet et al., 2007; Utter and Basso, 2008;
Rodriguez-Oroz et al., 2009).
Interesting data comparing cognitive performance following
DBS using the STN or the GPi can be collected from recently
published randomized trials. The COMPARE trial randomized 52
PD patients to receive unilateral DBS of either the STN or GPi
in a single center where staged surgery is customarily performed
(Okun et al., 2009). Forty-ﬁve patients were assessed using a pre-
planned protocol before and 7months after surgery, showing that
no differences could be observed between both targets regard-
ing cognitive outcomes, as assessed by verbal ﬂuency (VF) tasks
(letter and category). However, when analyzed independently, let-
ter VF declined more on the STN group as compared to the GPi
group, although no statistical signiﬁcance was reached (p< 0.03,
Frontiers in Neurology | Dementia April 2012 | Volume 3 | Article 66 | 2
Massano and Garrett DBS and cognition in Parkinson’s disease
predeﬁned signiﬁcance <0.025). Moreover, patients were tested
under four different stimulation conditions: optimal (i.e., active
contact on target), dorsal (i.e., active contact dorsal to the nucleus),
ventral (i.e., active contact ventral to the nucleus), and switched
off. No differences could be observed between the several condi-
tions and, interestingly, letterVF has been found to be worse in the
STNgroup regardless of the stimulation condition. Taken together,
these results suggest that surgical microlesion effects could play
an important role concerning cognitive outcomes in this setting.
On the other hand, the interesting issue of laterality has been
approached in this trial: an approximately equal number of right
and left-sided electrode implantationswere performed,andno sig-
niﬁcant differences could be observed between groups concerning
cognitive outcomes. Nonetheless, this trial does not reﬂect usual
clinical practice, as bilateral DBS of any of those targets is the rule,
so caution should be used when drawing predictions from these
data for most PD patients undergoing DBS.
Robust and clinically useful evidence on this matter is derived
from the work by Follett and colleagues, who conducted a large
randomized double-blind trial of STN DBS (n= 147) versus GPi
DBS (n= 152) in advanced PD. Patients were observed up to
24months after surgery, showing that both groups improved, and
that no differences could be found between them regarding motor
outcomes, self-reported function, QOL, and adverse events. Cog-
nitive performance declined in both groups equally except for
processing speed index, which declined more for the subthalamic
than for the pallidal stimulation patients (p= 0.03). Interestingly,
mood was also differentially affected, with GPi patients faring bet-
ter as mood improved slightly in the GPi DBS group, whereas it
worsened slightly in the STN DBS group. Medication was signif-
icantly reduced after surgery only in the STN DBS group (Follett
et al., 2010).
Another recent publication disclosed data on DBS using either
target. This international collaborative effort was ﬁrstly designed
as an open, non-randomized, prospective multicenter clinical
trial aimed at evaluating safety and effectiveness of bilateral STN
and GPi stimulation in advanced PD. Randomized double-blind
assessments with crossover on the second day of the 3-month
follow-up visit and unblinded assessments at 1-, 6-, and 12-month
follow-up were planned. An extension period was carried out
to collect data from the long-term (3–4, 5–6 years) and from a
double-blind randomized crossover evaluation at 5–6 years.At this
time point, 35 patients from the STN DBS group and 16 included
in the GPi DBS group were assessed and compared with the stim-
ulation randomly turned on and off. Double-blind assessments
conﬁrmed the effectiveness of stimulation in both groups con-
cerning motor outcomes. Dyskinesias and activities of daily living
were also signiﬁcantly improved, and medication had been signif-
icantly reduced in the STN group only. However, adverse events
were more common in the STN group, including cognitive decline
and speech difﬁculties, but further details have not been provided
in the manuscript (Moro et al., 2010).
A French collaborative research assessed patients undergoing
bilateral DBS (49 STN and 13 GPi) at baseline and 3–6months
after surgery. Neuropsychological testing included the Mattis
Dementia Rating Scale (MDRS), the Grober and Buschke Ver-
bal Learning Test, the Wisconsin Card Sorting Test, category and
literal ﬂuency, graphic and motor series, the Stroop Test, and the
trail making test (TMT). Motor improvements were noticeable in
both groups afterDBS,but lexical ﬂuency declined in the STNDBS
patients. However, these were not noticed by the patients or their
families, suggesting that this decline might be very subtle. On the
other hand TMT A and B, which evaluate selective attention and
cognitive ﬂexibility, improved in the STN DBS patients (Ardouin
et al., 1999).
Extending theirwork, the same research groupassessedwhether
turning the stimulation on and off would affect cognitive perfor-
mance in subthalamic and pallidal DBS. With the stimulation on,
STN patients showed a mild but signiﬁcant improvement in psy-
chomotor speed and working memory; they also showed a deﬁcit
of lexical ﬂuency at 12months after surgery. Stimulation status
did not seem to inﬂuence cognitive performance in the GPi group
(Pillon et al., 2000).
Volkmann and coworkers have conducted a retrospective study
aimed at comparing safety and efﬁcacy of subthalamic (n= 16)
and pallidal (n= 11) stimulation. Again, motor outcomes were
similar in both groups, with slight advantage to the STN patients
regarding off period symptom severity. Furthermore, antiparkin-
sonian medication was signiﬁcantly reduced in the latter patients,
who also required less energy delivery, but this group suffered a
higher frequency and severity of adverse events. Cognitive status,
as assessed by mini-mental state examination (MMSE) and the
Cambridge Examination for Mental Disorders Cognitive Subscale,
remained unchanged in both STN and GPi groups (Volkmann
et al., 2001).
Anderson et al. (2005) reported on the outcome in STN
(n= 10) versus GPi (n= 10) stimulation in PD at 12months after
surgery, ﬁnding similar motor beneﬁt in both groups, although
bradykinesia has suffered additional improvement with STN DBS.
Signiﬁcant cognitive decline was observed in two STN patients, as
compared to none in the GPi group.
Rothlind and collaborators conducted a complex study ran-
domly assigning 42 PD patients to DBS of either STN (n= 19) or
GPi (n= 23). Moreover, surgery was staged (i.e., unilateral stim-
ulation initially, with contralateral surgery performed later), thus
allowing intermediate cognitive assessment, on average 6months
after the ﬁrst lead was implanted. Twenty-nine patients subse-
quently underwent a second surgery for contralateral lead implan-
tation, and completed a second neuropsychological evaluation on
average 15months later. The authors have found that unilateral
surgery induced slight but statistically signiﬁcant decays of VF and
working memory, which has also been observed after the second
surgery.However,VFwas signiﬁcantly affected only after left-sided
implantation. There were few differences regarding cognitive per-
formance when considering each target, and these were observed
both in unilateral and bilateral DBS: visuomotor coordination and
manual dexterity declined slightlymore in the STNgroup,whereas
auditory workingmemorywas somewhatmore affected in theGPi
group (Rothlind et al., 2007).
Hariz et al. (2008) brought further data on this matter, by
assessing adverse events in STN (n= 49) and GPi (n= 20) stim-
ulated patients at 4 years of postsurgical follow-up from eight
centers. Adverse events were signiﬁcantly more frequent in the
STN group as compared to GPi, with neuropsychiatric disorders
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(including cognitive decline) leading the list, but no details can be
extracted from the manuscript with regard to the type of mental
deterioration.
Overall, evidence on cognitive performance following palli-
dal DBS in PD is shorter than the one available for subthalamic
DBS. However, the available data clearly suggests that the risk of
cognitive decline is lower whenever the GPi is target of choice,
unlike what has been observed for the STN. Pursuing this line of
thought,Rouaud and collaborators have recently looked at theGPi
as a potential alternative for subjects with cognitive deﬁcits advis-
ing against performing subthalamic DBS. Seventeen patients were
submitted to bilateral GPi DBS, nine of these exhibiting signiﬁ-
cant cognitive deterioration at the time of surgery. Final assess-
ment was carried out 6months after surgery. Taking the group
as a whole there were signiﬁcant improvements in parkinsonian
symptoms (including axial features), ﬂuctuations, and dyskine-
sias. A signiﬁcant beneﬁt on activities of daily living has also been
documented. On the other hand, neuropsychological assessment
remained unchanged. The authors argue that bilateral GPi DBS
is both effective and cognitively safe in advanced PD patients for
whom STN DBS is not a viable option due to cognitive decline or
dopa-resistant axial motor signs (Rouaud et al., 2010).
Taken together, these data suggest that STN and GPi possess
differential proﬁles of cognitive risk, thus favoring tailoring of
the surgical approach. In other words, until fresher data advises
otherwise, each patient should be assessed in detail and the tar-
get chosen according to his/her speciﬁc characteristics, including
cognitive status.
A limited amount of data has been published regarding cogni-
tion in PD patients undergoing DBS using the VIM nucleus of the
thalamus, probably due to the fact that this target is now seldom
used and earlier series where much smaller than those published
with STN or GPi stimulated patients. Caparros-Lefebvre and col-
laborators approached this issue in nine PD patients submitted to
VIM stimulation. Tremor response was quite satisfactory and neu-
ropsychological testing disclosed similar results before and after
surgery (Caparros-Lefebvre et al., 1992). Tröster and coworkers
have reported on a single case undergoing left unilateral VIM
stimulation, with testing carried out at 3-, 6-, and 18-months.
They have found that semantic VF was subtly improved while the
stimulationwas on, but in the very same condition short-term ver-
bal memory became impaired (Tröster et al., 1998). Woods et al.
(2001) analyzed cognitive performance of six PD patients at base-
line and 1 year after unilateral DBS of the VIM; the authors have
found that conceptualization and verbal memory suffered signif-
icant postsurgical decline, despite the improvements in QOL and
emotional functioning. Loher and coworkers analyzed cognitive
outcomes following VIM DBS in ﬁve PD patients, two essential
tremor patients, and two MS patients. Detailed neuropsycholog-
ical testing was carried out on and off stimulation, with a mean
follow-up of 9months. The authors found mild memory changes
while the stimulation was on but not when it was turned off, sug-
gesting that this change is related to the stimulation and not due
to microlesion effects (Loher et al., 2003).
In view of the results extracted so far from published data, we
will further detail on cognitive outcomes following subthalamic
DBS, as this seems a topic deserving further consideration.
DBS OF THE SUBTHALAMIC NUCLEUS: OUTCOME BY COGNITIVE
DOMAIN
Evidence collected so far has clearly demonstrated that DBS of
the STN in advanced PD is beneﬁcial regarding motor symptoms,
activities of daily living, and QOL,while levodopa equivalent daily
dose (LEDD) is signiﬁcantly reduced (Limousin et al., 1998; Krack
et al., 2003; Deuschl et al., 2006; Kleiner-Fisman et al., 2006; Witt
et al., 2008; Follett et al., 2010; Williams et al., 2010; Smeding
et al., 2011). However, as mentioned above, data has been accu-
mulating that shows the potential for cognitive changes following
the procedure, and several cognitive domains have been separately
explored in this regard. Deﬁning and assessing independent cog-
nitive domains is not a straightforward task, as several deﬁnitions
are often used for the same domain, and it is hard to independently
assess each cognitive function, for neural processes and behaviors
are inextricably intertwined. Frontal executive functions (FEx),
for instance, encompass several cognitive functions and processes,
for which various assessment tests have been devised (Funahashi,
2001; Godefroy, 2003; Miller and Cummings, 2007; Stuss and
Alexander, 2007). This might bring some interpretation problems,
as the different aspects of FEx may be differentially affected fol-
lowing STN DBS, something that has in fact been observed in a
few studies. A well-structured list of tests used for cognitive assess-
ment in DBS research can be found in the work by Parsons et al.
(2006).
Various studies have assessed global cognitive performance
before and after surgery, usually by means of the MMSE test or
the MDRS. Most authors have found no signiﬁcant postsurgi-
cal changes, thus suggesting that the procedure is generally safe
regarding cognition in well selected patients (further details can
be found in Table 1). The fact that different measures of global
cognition have been used could be potentially relevant, since it has
been shown that MMSE, a classically used instrument, has shown
low sensitivity to detect cognitive deterioration in PD (Hoops
et al., 2009; Kulisevsky and Pagonabarraga, 2009; Chou et al., 2010;
Kaszás et al., 2012). On the contrary, MDRS seems to have good
sensitivity and speciﬁcity scores for this purpose, which might
be due to the fact that it explores further cognitive domains and
deﬁcits in comparison to the MMSE, including frontal lobe and
fronto-subcortical cognitive decline, although it is more time con-
suming than MMSE (Kulisevsky and Pagonabarraga, 2009; Chou
et al., 2010; Kaszás et al., 2012). In fact, the MDRS Nonetheless,
MMSE has been recognized by the Movement Disorder Society
PD dementia workgroup as a potentially useful instrument in the
diagnostic process of PD dementia, but should not be used in
isolation with this purpose (Emre et al., 2007).
Several studies have found a signiﬁcant decline in phone-
mic (letter) VF, while semantic VF seemed to remain relatively
spared after DBS (Castelli et al., 2007; Okun et al., 2009; Zan-
gaglia et al., 2009), but others have observed signiﬁcant declines
in both VF modalities (Witt et al., 2008). Some studies convey
information of special interest, due to the fact that a control group
has also been included. Okun et al. (2009) have found interest-
ing results, as phonemic VF declined after unilateral STN DBS,
regardless of the active contact used and even with the stimulation
turned off. This suggests that such an impairmentmight arise even
after unilateral procedures and could result from microlesion or
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Table 1 | Publications concerning cognitive functioning after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease, at the
time of last cognitive assessment.
Publication Number of
patientsa
Follow-upb Agec Symptom
durationc
Improvement Worsening Unchanged
Limousin et al. (1998) 24 12months 56 14.0 – – A/FEx, GCP
Ardouin et al. (1999) 49 3–6months 54.7 15.1 A/FEx L GCP
Pillon et al. (2000) 63 6–12months 55.2 14.8 A/FEx, PMS L M
Alegret et al. (2001) 15 3months 61.1 16.1 A/FEx, PMS L, M, VS –
Lopiano et al. (2001) 16 3months 60.7 15.4 – – A/FEx, L, M
Perozzo et al. (2001) 20 6months 61.6 15.4 – – A/FEx, L, M,
PMS
Volkmann et al. (2001) 16 12months 60.2 13.1 – – GCP
Daniele et al. (2003) 20 12–18months 57 14.2 GCP, A/FEx L M
Funkiewiez et al. (2003) 50 3–48months 54.6 NR – – A/FEx, GCP
Krack et al. (2003) 49 5 years 55 14.6 – A/FEx GCP
Funkiewiez et al. (2004) 77 12–36months 55 15 – L A/FEx, GCP
Hershey et al. (2004) 24 2–15months 63 13 – A/FEx –
Morrison et al. (2004) 17 13.3weeks
(average)
59.9 10.8 – A/FEx, L GCP, M, VS
Witt et al. (2004) 23 6–12months 57.4 15.1 A/FEx (cognitive
ﬂexibility)
A/FEx (response
inhibition)
GCP, L
Schüpbach et al. (2005) 37 60months 54.9 15.2 – A/FEx, GCP –
Castelli et al. (2006) 72 15months
(average)
60.5 15.1 A/FEx (set
shifting)
L A/FEx
(attention,
reasoning), M
De Gaspari et al. (2006) 26 15months
(average)
59.8 15.8 – L GCP
Deuschl et al. (2006) 78 6months 60 NR – – GCP
Erola et al. (2006) 29 12months 60 13 – L A/FEx
Smeding et al. (2006) 103 6months 57.9 13.7 – A/FEx, L, M –
Temel et al. (2006) 39 13.6months
(average)
60 15.5 PMS – –
Aybek et al. (2007) 57 34.3months
(average)
63.8 15.7 – A/FEx, C, M, P
(constructive)
L, VS, P
(ideomotor)
Castelli et al. (2007) 19 17months
(average)
62.1 14.7 – L (phonemic VF) A/FEx, M, L
(semantic VF)
Ory-Magne et al. (2007) 45 24months 60 13.5 – – A/FEx, L, M
Rothlind et al. (2007) 19 15months 61.4 12.9 – A/FEx (attention,
working
memory), L
A/FEx
(executive
functions), M
York et al. (2008) 23 6months 59.5 12.0 – L, M GCP, A/FEx, VS
Heo et al. (2008) 46 12months 58 11.4 – A/FEx (attention,
interference
sensitivity), L, M
GCP, A/FEx
(reasoning),
PMS
Witt et al. (2008) 60 6months 60.2 13.8 – A/FEx, L GCP, M, VS
Denheyer et al. (2009) 16 16months
(average)
– L A/FEx
Okun et al. (2009) 26 7months
(average)
59.8d 13.3d – L (phonemic VF) L (semantic VF)
Zangaglia et al. (2009) 32 36months 58.8 11.8 – A/FExe, L GCP, M
Fasano et al. (2010) 20 96months
(average)
56.9 13.7 – A/FEx, L, M GCP
Kishore et al. (2010) 45 5 years 55.4 11.1 – – A/FEx, GCP, L,
M, VS
(Continued)
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Table 1 | Continued
Publication Number of
patientsa
Follow-upb Agec Symptom
durationc
Improvement Worsening Unchanged
Merola et al. (2011) 19 7.9 years
(average)
61.5 22.8 – A/FEx, L, M –
Smeding et al. (2011) 105 12months 58.4 13 – A/FEx, GCP, L,
M
–
Williams et al. (2011) 19 2 years 62.1 10.1 – L, M A/FEx, GCP, VS
Results presented here exclude any cognitive deﬁcits directly attributed to well-deﬁned adverse events (e.g., intraparenchymal hematoma). Further details are pro-
vided whenever diverse aspects of the same cognitive domain are differentially impaired in the same study. Legend: aincluded at baseline; btime after DBS for the
last cognitive assessment; cmean or median, at the time of DBS; drefers to those assessed cognitively only (n=22); edecline seen 6months after DBS, but same
performance as controls after 12months; NR, data not reported; A/FEx, attention and frontal executive functions; C, calculation; GCP, global cognitive performance;
L, language; M, memory; P, praxis; PMS, psychomotor speed; VF, verbal ﬂuency; VS, visual/spatial capabilities.
insertion effects. Witt and collaborators have conducted a mul-
ticenter controlled study enrolling patients for either STN DBS
(n= 60) or best medical therapy (n= 63). By the end of the 6-
month study period following DBS, they have found thatVF (both
phonemic and semantic) and executive functions had declined
signiﬁcantly in the surgical group, but this ﬁnding was indepen-
dent of the observed improvement in QOL, and global cognition
remained unaffected (Witt et al., 2008). In their series of 77 consec-
utive PD patients undergoing subthalamic DBS Funkiewiez et al.
(2004) have observed that semantic ﬂuencywas signiﬁcantlyworse
1 and 3 years after surgery, when compared with the preoperative
score. However, the difference between 1 and 3 years after surgery
is not signiﬁcant, suggesting that this is an early adverse effect
of the therapy. Zangaglia and coworkers have observed results
somewhat different from those found by other authors. In their
study, 32 patients underwent STN DBS while 33 were enrolled
as controls, after having refused surgery, choosing medical treat-
ment instead. Six months after surgery, DBS patients had shown
signiﬁcant declines in both phonemic VF and FEx; however, the
cognitive proﬁle had returned to the values obtained before the
surgical procedure by 12months, remaining stable 3 years after
surgery (Zangaglia et al., 2009). These ﬁndings seem to be in con-
ﬂict with other publications, but comparing results is a challenging
task, since the few studies controlled by a medical treatment group
conducted so far had shorter follow-up periods. A 12-month long
studywas conducted by Smeding et al.,who enrolled 105 STNDBS
patients and 40 medically treated controls. In the surgical group a
decline in cognitive performance has been noted in 36%percent of
patients; signiﬁcant changes were seen in global cognitive perfor-
mance, VF, verbal memory, and executive functions. The authors
argue that this does not seem to be a transient consequence, since
effect sizes of most cognitive changes had become even larger from
6 to12months.Despite experiencing cognitive decline,9%of these
patients reported improvements in QOL, suggesting that cognitive
decline does not necessarily mean a loss of clinical beneﬁts gained
from the surgical procedure (Smeding et al., 2011). The study by
Williams et al. (2011) included 19 patients undergoing STN DBS
and 18 medically treated PD controls; the ﬁnal cognitive assess-
ment was performed 2 years after surgery. Patients undergoing
DBS displayed signiﬁcant decline of phonemic and semantic VF,
as well as non-verbal recall and information processing speed.
An array of data regarding FEx following STN DBS has been
published, but conclusions are considerably harder to analyze
than for VF. Several studies have reported that FEx worsen after
STN DBS, whereas an approximately equal number has found
unchanged scores after the procedure (see Table 1 for details).
Of course, there are methodological differences between studies,
and this might contribute for the disparities, but one must keep
in mind that research groups have used widely accepted crite-
ria for surgical patient selection, and the tests used for cognitive
assessment are similar in many studies. Also, mean age at time
of DBS and disease duration do not seem to differ signiﬁcantly
amongst most studies (Table 1). Hence, other factors probably
account for the differences. FEx are particularly difﬁcult to deﬁne
and assess, as several different processes are encompassed under
this umbrella term (Funahashi, 2001; Godefroy, 2003; Miller and
Cummings, 2007; Stuss and Alexander, 2007). Therefore, strict
deﬁnitions and assessment uniformization would clearly be useful
in order to allow effective comparison of data published by the dif-
ferent study groups and eventually produce future meta-analyses
of results. Other cognitive domains have been assessed, and Table 1
qualitatively summarizes the ﬁndings from each study.
Longer term data has also been published. Fasano et al. have
reported their ﬁndings on a group of 20 STN DBS patients fol-
lowedup for 8 years after surgery. The authors have found that part
of the motor beneﬁt had been lost since the previous assessment
3 years before, due to levodopa- and stimulation-resistant symp-
toms. On the other hand, they have found signiﬁcant declines in
VF, episodic memory, and executive functions, but only memory
had signiﬁcantly declined from 5 to 8 years of follow-up. Exec-
utive functions correlated signiﬁcantly with postural instability
(PI), which is not a surprising result, as both cognitive deteriora-
tion and PI are to be expected along disease progression – however,
questions remain regarding putative common pathophysiological
mechanisms or interactions. One patient had developed dementia
at 5 years after DBS, with further progression at 8 years (Fasano
et al., 2010).
The mechanisms leading to cognitive changes following STN
DBS remain both intriguing and enigmatic. The STN seems to
play an important role not only in motor function, but also
in limbic and associative neural networks (Mallet et al., 2007;
Rodriguez-Oroz et al., 2009; Volkmann et al., 2010). This nucleus
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incorporates the basal ganglia circuitry, and has traditionally been
included in the so-called “indirect-pathway” inhibiting thalamo-
cortical excitability (Obeso et al., 2008). It has been recognized that
the dorsolateral portion of the STN is involved in motor function,
while the intermediate part is important for cognitive processes
and the anteromedial portion seems to be implicated with emo-
tion (Mallet et al., 2007; Rodriguez-Oroz et al., 2009; Volkmann
et al., 2010). Conceivably, although electrical stimulation in PD is
meant to modulate motor circuitry, the energy pulse could extend
to nearby non-motor regions in the STN and affect both emo-
tion and cognitive performance, including VF. This also implies
that the STN must play an important role with regard to cognitive
processes, with a special clinical relevance for those involved inVF.
This has also been suggested by functional neuroimaging research,
namely PET scan, such as the work from Schroeder et al. (2003),
who demonstrated that regional cerebral blood ﬂow (rCBF) of
the right orbitofrontal cortex and VF-associated rCBF within left-
sided frontotemporal regions became notoriously reduced during
STN stimulation compared with the off stimulation condition,
which suggests that STN stimulation reduces the activation of a
VF-related frontotemporal network.
In any case, the mechanisms underlying postsurgical cognitive
decline remain obscure, and could be multifactorial, with the pos-
sible implication of individual and therapy-related risk factors.
For example, it is currently unknown whether the trajectory of
the electrodes, which are inserted through the frontal lobes and
often cross the caudate nucleus, inﬂuences the cognitive outcome
(Volkmann et al., 2010).
DEMENTIA FOLLOWING SUBTHALAMIC DBS IN PD PATIENTS
It would be important to know the incidence rate of dementia
after DBS and whether this is in consonance with the natural his-
tory of the disease or if, on the other hand, there is an inﬂuence
exerted by the surgical procedure itself or the stimulation. So far,
data have not been conclusive, as there is a paucity of controlled
and long-term studies aimed at looking into this issue. The stud-
ies considered here have demonstrated signiﬁcant beneﬁts with
regard to motor symptoms and QOL, in accordance to what has
been described by other authors.
The experienced Grenoble group has analyzed outcomes of
STN DBS in 49 PD patients 5 years after surgery, and has found
that three patients developed dementia (according to the Diag-
nostic and Statistical Manual of Mental Disorders fourth edition
criteria) 3 years after surgery, which corresponds to a prevalence
of 6% (Krack et al., 2003). Importantly, two of these patients
had become demented within 3months after surgery, which is
a matter of concern, since neuropsychological testing and clinical
observation had been rigorously carried out preoperatively.
Castelli et al. (2007) have published their ﬁndings from 19
patients submitted to STN DBS, assessed at baseline and at a
mean of 17months after surgery. None of the patients developed
dementia in this series.
York and coworkers designed a 6-month controlled study, and
included 23 PD patients who underwent STN DBS, as well as
28 medically treated PD controls. The authors have found that
one patient (4%) had developed dementia 6months after surgery,
and two others had signiﬁcant cognitive decline but did not fulﬁll
criteria for dementia (York et al., 2008). The former patient was
14 years older than the average age in the series, had several vas-
cular risk factors, and preoperative MRI had shown small vessel
subcortical ischemic lesions. However, his cognitive, clinical, and
psychiatric assessments did not contraindicate DBS. Postoperative
CT scan has shown a small intraventricular hemorrhage and the
patient suffered from transient postoperative confusion.
The study by Ory-Magne et al. (2007) has shown that 3 out
of 45 patients developed dementia after a follow-up period of
24months.
From Switzerland, Aybek et al. (2007) have obtained quite dif-
ferent results, as they prospectively assessed 57 patients submitted
to STNDBSover 3 years. In this series, 24.5%of patients developed
dementia over 3 years, whereas the remainder maintained stable
cognitive scores. Those who became demented were on average
older, displayed poorer executive performance, and a higher fre-
quencyof hallucinations. The average ageof this series is somewhat
higher than what can been observed in others, where lower inci-
dence rates of dementia have been found. The authors argue that
the incidence rate of dementia in this cohort is similar to what
has been observed in medically treated patients, thus in keeping
with the natural history of PD. Nonetheless, they agree that fur-
ther studies should be conducted in order to deﬁne risk factors for
developing dementia after DBS, especially because 36% of patients
developing dementia did sowithin 6months after surgery, suggest-
ing a triggering effect of the procedure or the stimulation. From
the same group, a longer observation period which included addi-
tional subjects has shown that 20% of patients (14/70) developed
dementia on average 25months after surgery (Aybek et al., 2009).
Zangaglia and collaborators where able to conduct a 3-year
prospective study of STN DBS patients (n= 32) and medically
treated controls who declined surgery (n= 33); at the time of last
assessment one patient had become demented and one other had
developed mild cognitive impairment in the surgery group only.
The former patient had long disease duration (>21 years) at the
time of DBS, when she was 60. Her MMSE score was at the lower
limits of normal (24/30), and her preoperative l-dopa test had
shown improvement of 56–36 in the Uniﬁed PD Rating Scale part
III score (Zangaglia et al., 2009).
In the above mentioned series by Fasano et al. (2010) which
included 20 patients with a follow-up of 8 years, only one patient
developed dementia.
Kishore and colleagues have published results on 49 patients,
29 of them assessed at 5 years. At this time point ﬁve patients had
become clinically demented; all of these had shown mild cogni-
tive changes in baseline neuropsychological testing (Kishore et al.,
2010).
The studybyCastrioto et al. reveals data extractedduring longer
follow-up, as 18 patients were assessed 10 years after surgery. The
authors have shown that motor beneﬁts are still signiﬁcant by
this time as compared to baseline, although progressive decline
has been observed, especially with regard to axial features. Three
patients developed dementia in this series (Castrioto et al., 2011).
Williams et al. (2011) conducted a 2-year long controlled study,
which enrolled 19 STN DBS patients and 18 medically treated
PD controls. Two patients fulﬁlled criteria for dementia 6months
after surgery, and six patients at 2 years, twice as much as in the
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control group, but based on frequencies this was statistically not
signiﬁcant (p= 0.21). In addition, the authors have analyzed MCI
frequency in this study, deﬁned by a deﬁcit of at least 2 SDs below
the age corrected mean in one of the four cognitive domains iden-
tiﬁed in a recent expert consensus (Emre et al., 2007). Baseline
MCI frequencies were similar in both groups. Three of the ﬁve
stimulated patients who met criteria for MCI at baseline, had
developed dementia, whereas the remaining two still fulﬁlled cri-
teria for MCI at 2 years. In the control group all three PD patients
with MCI at baseline had developed dementia by the time of the 2-
year postsurgical evaluation. Moreover, at 2 years, four additional
STN DBS patients fulﬁlled criteria for MCI, compared to three
controls. When combining MCI and dementia patients, a trend
has been observed toward higher cognitive deterioration in the
surgery group (p= 0.06).
In summary, data coming from these studies seems somewhat
divergent, but one must keep in mind methodological differences.
Some studies suggest that cognitive decline follows the natural
history of PD, whereas others have shown that a signiﬁcant num-
ber of patients develop dementia in the ﬁrst few months after
implantation. This is an intriguing ﬁnding, and one may won-
der if certain patients have some sort of speciﬁc vulnerability to
accelerated postsurgical cognitive decline.
COGNITIVE OUTCOME FOLLOWING DBS OF THE SUBTHALAMIC
NUCLEUS: PREDICTIVE FACTORS
A few studies have tried to delineate predictors of cognitive decline.
However, the evidence published on this matter is limited.
Funkiewiez et al. (2004) have studied 77 PDpatients up to three
3 years after surgery; category VF was found to have signiﬁcantly
declined in this series. Patient preoperative age correlated signiﬁ-
cantly with the decay of a previously described frontal lobe score
(Pillon et al., 1986) and the initiation subtest of MDRS.
The study by Ory-Magne and coworkers explored a possible
role of age on clinical outcome following subthalamic DBS; 45
patients with a mean age of 60 years (range 40–73) were enrolled,
43 were reassessed at 12months, and 39 at 24months. The authors
have found that cognitive and motor outcomes were unrelated to
patient age at the time of DBS, but younger patients sustained
greater improvements in QOL (Ory-Magne et al., 2007).
The study carried out by Rothlind et al. (2007) has failed to
demonstrate any relation between postoperative cognitive changes
and age or reductions in levodopa equivalent dose after surgery.
Heo and colleagues studied cognitive changes after STN DBS
in 46 PD patients, who were assessed at 6months and 1 year after
surgery. At these time points VF had declined; mild declines have
also been found in memory and executive functions. Higher for-
mal education, higher levodopa equivalent dose, and younger age
at onset correlated with cognitive worsening, but age at the time
of DBS has not been found to be a predictor of decline (Heo et al.,
2008).
Aybek and coworkers have found that, in their series of 70 PD
patients, 14 developed dementia after an average of 25months
postsurgery. These were compared with 14 controls and the
authors have found that hippocampal atrophy is a predictor of
dementia in PD patients converting to dementia after subthalamic
DBS (Aybek et al., 2009).
The above mentioned study by Smeding et al. also approached
the issue of predictors of postsurgical decline. This controlled
study has found that patients with advanced age, impaired base-
line attention, and poorer levodopa response are at greater risk
for postsurgical cognitive decline; importantly, the correlation
between these factorswas low,andmulticollinearitywas not signif-
icant, suggesting that their correlation with postsurgical cognitive
deterioration is probably independent (Smeding et al., 2011).
In summary, the amount of evidence speciﬁcally concerning
the issue of predictors of cognitive decline following DBS is some-
what small. Keeping in mind the natural history of PD (Lim
et al., 2009; Rajput et al., 2009; Hawkes et al., 2010), one could
postulate that certain factors would eventually predict cognitive
decline following STN DBS, such as advanced age, axial signs, lev-
odopa resistant symptoms, visual hallucinations, vascular lesion
load, and poor baseline cognitive performance. Although the intu-
itive notion that, for instance, age would predict cognitive decline
seems logical, the ﬁndings from the several studies published so
far have not settled this question. This is also valid for other vari-
ables; importantly, many of them have not even been tested in the
published research literature.
PSYCHIATRIC AND BEHAVIORAL EFFECTS OF DBS IN PD
Deep brain stimulation in PD has been frequently associated with
behavioral and psychiatric symptoms, which have been mostly
reported in association with STN DBS (Voon et al., 2006; Volk-
mann et al., 2010). Although this is not the main focus of the
present manuscript, this matter should be here brieﬂy mentioned,
due to its clinical relevance.
Apathy is frequently diagnosed in PD patients, but the over-
lap and confusion with depression and cognitive impairment
(including dementia) are common (Starkstein, 2012). Data on
postsurgical apathy is quite variable, but this seems to be a frequent
adverse event following STN DBS (Voon et al., 2006; Volkmann
et al., 2010; Starkstein, 2012).
Elevation of mood has been reported following STN DBS;
euphoria; or hypomania have been described in up to 15% of
patients, whereas mania probably occurs in less than 2% of cases
(Voon et al., 2006; Volkmann et al., 2010). A decrease in stimula-
tion levels or dopaminergic drugs may be necessary for symptom
remission; alternatively, switching the active contact to a more
dorsal position could be tried. Depression has been reported in
up to 25% of patients during postsurgical follow-up (Voon et al.,
2006; Volkmann et al., 2010). Results from the COMPARE trial
have suggested that more ventral contacts carry the ability to
induce depressive feelings, as compared to more dorsal contacts
(Okun et al., 2009). The recent randomized trial conducted by the
CSP 468 Study Group has shown that depression worsened after
STN stimulation, whereas it improved after pallidal stimulation
(p= 0.02), despite the fact the both groups of patients improved
similarly regarding motor symptoms and self-reported function
(Follett et al., 2010). Interestingly, mood disorders tend to occur
in the ﬁrst few months after surgery (Voon et al., 2006; Volkmann
et al., 2010).
Postsurgical suicide is a leading concern in the setting of STN
DBS. A large international multicentre study involving more than
5000 patients has shown that the attempted and completed suicide
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rates can be estimated at 0.90 and 0.45%, respectively (Voon et al.,
2008). Suicide rates were higher in the ﬁrst postoperative year
and remained high in the fourth year, as compared to the adjusted
WorldHealthOrganization suicide rates. The excess death number
was 13 in the ﬁrst year, declining to one in the fourth. Attempted
suicide risk has been related to postoperative depression, being
single, a previous history of impulse control disorders, or com-
pulsive medication use, being younger, younger PD onset, and
a previous suicide attempt. Completed suicides were associated
with postoperative depression, which remained a signiﬁcant fac-
tor associated with attempted and completed suicides even after
statistical correction (Voon et al., 2008). Also, it has been shown
that impulsivity scores following STN DBS increase (Hälbig et al.,
2009). However, the implications for suicide have not been ade-
quately established, although one might speculate that this could
cause greater propensity for impetuous self-destructive behaviors.
A range of impulsive compulsive behaviors (ICBs) have been
described in PD, in association with dopaminergic drug therapy
(Evans et al., 2009; Djamshidian et al., 2011). One would expect
that STN DBS could improve ICBs by facilitating a decrease of
postoperative dopaminergic medication. Unfortunately, the avail-
able evidence concerning this issue is not robust, and the outcomes
regarding the effect of DBS on ICBs are conﬂicting, as published
data have disclosed mixed results (Broen et al., 2011).
In most studies a decrease in anxiety levels has been reported
(Volkmann et al., 2010).
It remains unclear which mechanisms underlie, and which
risk factors associate with, the behavioral and psychiatric disor-
ders observed after STN DBS. For instance, it has been suggested
that the common postoperative reduction of dopaminergic drugs
might play a role in the case of apathy or depression, but surgery
itself or electrical stimulation could also be involved (Voon et al.,
2006; Volkmann et al., 2010). On the other hand, an array of
factors such as previous psychiatric disorders, personality traits,
and psychological and psychosocial aspects might also play an
important role.
Psychiatric symptoms warrant dedicated management before
and after surgery, and their nature or severity may even advise
against STN DBS in PD. Useful recommendations regarding man-
agement have been issued by experts in the ﬁeld (Lang et al., 2006;
Voon et al., 2006). This is an area of major concern and it has
become clear that patient selection for DBS should be carried out
by incorporating also psychiatric symptoms as important vari-
ables. In any event, patients should be informed beforehand of the
expected risks in associationwith the procedure, especially suicide.
As mentioned above, the choice of brain target for stimulation
should probably be considered on a tailored perspective.
CONCLUSION
From the evidence collected so far, it seems reasonable to con-
sider that DBS is generally safe from the cognitive standpoint in
well selected PD patients, especially when looking at measures of
global cognition. Nonetheless, there is a clear risk of postsurgical
cognitive decline, which seems greater whenever the STN is used,
although data concerning other targets is scanter. On the other
hand, robust evidence based data is not proliﬁc, with only one
large randomized, double-blind trial conducted thus far, which
has focused mainly on motor efﬁcacy issues of STN DBS versus
GPi DBS (Follett et al., 2010).
Postsurgical decline in VF has been the most consistently
reported cognitive adverse effect in patients undergoing subthal-
amic DBS. Interestingly, our experience over the last decade, after
around 200 PD patients already treated with DBS, suggests that
patients are willing to accept such a tradeoff, as the motor beneﬁts
gained from the procedure seem, from their subjective point of
view, to compensate for the VF changes observed. It would prob-
ably also be pertinent to systematically and objectively collect the
opinions from families and caregivers on this matter, in order to
conﬁrm this impression, as frontal lobe dysfunction could bias
patient self-assessment.
Several questions remain unanswered. First, it is difﬁcult to
demonstrate long-term effects of the surgical procedure or stim-
ulation, and to differentiate these from the natural progression of
the disease, as well as other confounding variables (e.g., effects of
drug therapy, brain vascular lesions, PD progression, and concur-
rent degenerative pathology). Short-term clear cut changes (e.g.,
6–12months after surgery) are most probably due to the surgi-
cal procedure itself and/or the electrical stimulation – some small
controlled studies, above mentioned, have suggested this. On the
other hand, available data suggests that some aspects of cognitive
functioning remain unchanged or even improve. Finally, so far it
has not been explored what these postsurgical cognitive changes
imply in terms of QOL and daily functioning. This seems to be
an important issue, since medical decisions, as well as presurgical
patient information and choices would largely beneﬁt from this
kind of evidence.
In some studies, dementia cases have been detected a few
months after the surgical procedure, which is an intriguing and
disturbing fact. Nonetheless, there is large heterogeneity between
study results concerning this matter. Dementia cases should be
systematically recorded and published, using well recognized diag-
nostic criteria – currently, the proposal by Emre et al. (2007) seems
the most comprehensive one, and conveys the ﬁrst diagnostic rec-
ommendations aimed speciﬁcally at PD dementia, although, to
the best of our knowledge, prospective validation in large cohorts
has not been reported so far.
In addition, research on predictive factors of postsurgi-
cal decline remains unsatisfactory, as this topic has not been
approached in detail, and even at all, in most studies. Anyhow,
the identiﬁcation of predictive factors of outcome would be of
great help, since it would allow better patient selection and infor-
mation concerning the risk of poor cognitive outcome after DBS.
Emphasis should probably be placed in risk factors for cogni-
tive decline in PD (Williams-Gray et al., 2007; Aarsland and Kurz,
2010) but maybe also for dementia, broadly speaking (Korczyn
and Vakhapova, 2007; Qiu et al., 2007). Notably, age, years of for-
mal education, PD duration, disease phenotype, axial symptoms,
levodopa responsiveness, hallucinations, and baseline cognitive
performance seem good research candidates. One wonders if cer-
tain genetic factors may also play a role, such as apolipoprotein E
polymorphisms or glucocerebrosidase mutations, and it would be
very exciting to explore this matter through large multicenter col-
laborative research initiatives. Preoperative imaging markers such
as vascular lesion load and atrophy of speciﬁc brain regions or
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whole brain volume would also probably deserve further explo-
ration. It would certainly be an interesting and useful achievement
to be able to stratify patients according to their risk based on a
number of features, eventually even using objective mathematical
and statistical models.
A large international agreement is clearly needed concerning
detailed cognitive assessmentmethodology and cutoff scores in the
setting of DBS for PD, for it seems difﬁcult to devise strict recom-
mendations based solely on the currently available data. It seems
that expert analysis and common sense are still paramount at this
point. Ideally, well founded consensus guidelines should be issued
and prospectively assessed in large well designed multicenter
trials.
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